Cover Image
Market Research Report

Schizophrenia Drugs Market Analysis, By Therapeutic Class (Second-Generation, Third-Generation Antipsychotics), By Treatment (Oral, Injectables), By Major Markets, And Segment Forecasts, 2016 - 2022

Published by Grand View Research, Inc. Product code 600802
Published Content info 103 Pages
Delivery time: 2-3 business days
Price
Back to Top
Schizophrenia Drugs Market Analysis, By Therapeutic Class (Second-Generation, Third-Generation Antipsychotics), By Treatment (Oral, Injectables), By Major Markets, And Segment Forecasts, 2016 - 2022
Published: November 3, 2017 Content info: 103 Pages
Description

The global schizophrenia drugs market is expected to be valued at USD 7.9 billion by 2022, as per a new report by Grand View Research, Inc. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.

Schizophrenia imposes substantial burden on patients, their families and the overall society. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.

The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.

Further key findings from the report suggest:

  • The global schizophrenia drugs market is segmented by therapeutic class into first, second and third-generation antipsychotics
  • Few of the prominent players operating in this industry are Johnson & Johnson, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Sumitomo Dainippon, Eli Lilly, Alkermes, Vanda Pharma, Allergan and Pfizer
  • Several market players are expected to work upon serving the unmet market needs, identifying new targets and consequentially develop stronger drug pipelines
  • The market share captured by generics is expected to grow by 2022, due to branded drugs losing their patent exclusivity and becoming generic
  • Regionally, among the EU5 markets, Germany captured the second position in the global schizophrenia drugs market. Japan is expected to witness the fastest growth over the forecast period
  • China and India are emerging as an opportunity for market expansion
Table of Contents
Product Code: GVR-2-68038-222-8
x

Table of Contents

Chapter 1 Research Methodology

  • 1.1. Information procurement
  • 1.2. Information or Data Analysis
    • 1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

  • 3.1 Chapter Summary
    • 3.1.1 Disease Primer
    • 3.1.2 Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU 5)

Chapter 4 Global Market Overview

  • 4.1 Chapter Summary
  • 4.2 Introduction and Market Overview
  • 4.3 Market, by Therapeutic Class
  • 4.4 Market Size and Forecast
  • 4.5 Sales Performance, by Drug Class
  • 4.6 Market Shares Distribution
  • 4.7 Market Dynamics Among Leading Brands
  • 4.8 Patent Expiry Analysis
  • 4.9 Schizophrenia Market: Drivers and Restraints
    • 4.9.1. Drivers
    • 4.9.2. Challenges
  • 4.10. M&A, Deal Landscape (2013-2017 YTD)
    • 4.10.1. Mergers & Acquisitions
    • 4.10.2. Deals Landscape
  • 4.11. Emerging Markets
  • 4.12. Pricing and Reimbursement Scenario
  • 4.13. Schizophrenia Sector SWOT

Chapter 5 Pipeline Intelligence

  • 5.1. Pipeline Landscape
    • 5.1.1. Leading Drugs in Development
    • 5.1.2. Key R&D Trends
  • 5.2. Pipeline Landscape
    • 5.2.1. Late Stage Pipeline Drugs
    • 5.2.2. Profiles of Disruptive Drugs
    • 5.2.3. Global Pipeline Forecast

Chapter 6 Company Profiles

  • 6.1. Chapter Summary -
  • 6.2. Johnson & Johnson
    • 6.2.1. Company Overview
    • 6.2.2. Current Product Portfolio
    • 6.2.3. Product Forecast Sales through 2022
    • 6.2.4. Strategic Initiatives
      • 6.2.4.1. Key Company News Flow
    • 6.2.5. SWOT
  • 6.3. Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals
    • 6.3.1. Company Overview
    • 6.3.2. Current Product Portfolio
    • 6.3.3. Product Forecast Sales through 2022
    • 6.3.4. Strategic Initiatives
      • 6.3.4.1. Key Company News Flow
    • 6.3.5. Catalysts and Event Calendar
    • 6.3.6. Pipeline Analysis and Overview
    • 6.3.7. SWOT
  • 6.4. AstraZeneca
    • 6.4.1. Company Overview
    • 6.4.2. Current Product Portfolio
    • 6.4.3. Product Forecast Sales through 2022
    • 6.4.4. Strategic Initiatives
      • 6.4.4.1. Key Company News Flow
    • 6.4.5. SWOT
  • 6.5. Eli Lilly
    • 6.5.1. Company Overview
    • 6.5.2. Current Product Portfolio
    • 6.5.3. Product Forecast Sales through 2022
    • 6.5.4. Strategic Initiatives
      • 6.5.4.1. Key Company News Flow
    • 6.5.5. SWOT
  • 6.6. Alkermes
    • 6.6.1. Company Overview
    • 6.6.2. Current Product Portfolio
    • 6.6.3. Product forecast sales through 2022
    • 6.6.4. Strategic Initiatives
      • 6.6.4.1. Key Company News Flow
    • 6.6.4. Pipeline Analysis & Overview
    • 6.6.5. SWOT
  • 6.7. Sumitomo Dainippon Pharma
    • 6.7.1. Company Overview
    • 6.7.2. Current Product Portfolio
    • 6.7.3. Product Forecast Sales through 2022
    • 6.7.4. Strategic Initiatives
      • 6.7.4.1. Key Company News Flow
    • 6.7.5. Pipeline Analysis & Overview
    • 6.7.6. Pipeline Forecast
    • 6.7.7. SWOT
  • 6.8. Pfizer
    • 6.8.1. Company Overview
    • 6.8.2. Current Product Portfolio
    • 6.8.3. Product Forecast Sales through 2022
    • 6.8.4. Strategic Initiatives
      • 6.8.4.1. Key Company News Flow
    • 6.8.5. Pipeline Analysis & Overview
    • 6.8.6. SWOT
  • 6.9. Vanda Pharmaceuticals
    • 6.9.1. Company Overview
    • 6.9.2. Current Product Portfolio
    • 6.9.3. Product Forecast Sales through 2022
    • 6.9.4. Strategic Initiatives
      • 6.9.4.1. Key Company News Flow
    • 6.9.5. SWOT
  • 6.10. Allergan (Forest Labs)/ Geodon Ritcher
    • 6.10.1. Company Overview
    • 6.10.2. Current Product Portfolio
    • 6.10.3. Product Forecast Sales through 2022
    • 6.10.4. Strategic Initiatives
      • 6.10.4.1. Key Company News Flow
    • 6.10.5. SWOT

Chapter 7 Market Outlook

  • 7.1. What the Future Holds
  • 7.2. The Winners and Losers
  • 7.3. Emerging Companies/New Technology Platforms
  • 7.4. The Road Ahead

List of Tables

  • TABLE 1 Age and Gender Specific Prevalence of Schizophrenia in the U.K.
  • TABLE 2 U.S. Patents for Current Schizophrenia Drugs
  • TABLE 3 Total and Per Patient Cost for Schizophrenia by Region
  • TABLE 4 R&D Pipeline Overview
  • TABLE 5 Late Stage Pipeline
  • TABLE 6 Pipeline Forecast
  • TABLE 7 Johnson & Johnson- Product Forecast Sales through 2022
  • TABLE 8 Bristol-Myers Squibb/ Otsuka Pharma- Product Forecast Sales through 2022
  • TABLE 9 AstraZeneca- Product Forecast Sales through 2022
  • TABLE 10 Eli Lilly- Product Forecast Sales through 2022
  • TABLE 11 Alkermes- Product Forecast Sales through 2022
  • TABLE 12 Sumitomo Dainippon- Product Forecast Sales through 2022
  • TABLE 13 Pfizer- Product Forecast Sales through 2022
  • TABLE 14 Vanda Pharma- Product Forecast Sales through 2022
  • TABLE 15 Allergan- Product Forecast Sales through 2022

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Positive Symptoms Associated with Schizophrenia
  • FIG. 8 Negative Symptoms Associated with Schizophrenia
  • FIG. 9 Cognitive Symptoms Associated with Schizophrenia
  • FIG. 10 Lifetime Risk of Schizophrenia
  • FIG. 11 Percentage of Schizophrenia Onset by Age and Gender
  • FIG. 12 Age and Gender Specific Prevalence of Schizophrenia in the U.S.
  • FIG. 13 Age and Gender Specific Incidence of Schizophrenia in the U.S.
  • FIG. 14 Age and Gender Specific Prevalence of Schizophrenia in Europe
  • FIG. 15 Incidence of Schizophrenia Based on Ethnic Group in the U.K.
  • FIG. 16 Prevalence of Schizophrenia in Japan
  • FIG. 17 Regional Market Size 2016-2022
  • FIG. 18 Market Share, by Drug Class 2016-2022
  • FIG. 19 Market Share, by Mode of Administration- Oral vs LAIs 2016-2022
  • FIG. 20 Market Shares, by Company 2016-2022
  • FIG. 21 Schizophrenia Sector SWOT
  • FIG. 22 Johnson & Johnson SWOT Analysis
  • FIG. 23 Bristol-Myers Squibb/ Otsuka Pharma SWOT Analysis
  • FIG. 24 AstraZeneca SWOT Analysis
  • FIG. 25 Eli Lilly SWOT Analysis
  • FIG. 26 Alkermes SWOT Analysis
  • FIG. 27 Sumitomo Dainippon SWOT Analysis
  • FIG. 28 Pfizer SWOT Analysis
  • FIG. 29 Vanda Pharma SWOT Analysis
  • FIG. 30 Allergan SWOT Analysis
Back to Top